Advance Autoimmune Therapy With the Only Dedicated T-Cell Engager Conference
As the promise of T-cell engagers (TCEs) extends beyond oncology, the T-Cell Engager for Autoimmune Disease Summit stands as the only hyper-focused industry event dedicated to accelerating TCE development specifically for autoimmune indications. This exclusive forum brings together top immunology researchers and drug developers to address key challenges, from overcoming cytokine release syndrome (CRS) and refining CD3 affinity to achieving targeted tissue depletion and unlocking novel autoimmune targets beyond B-cells.
Join academic thought leaders from FAU Erlangen-Nürnberg and industry trailblazers including executives from AstraZeneca, Candid Therapeutics, Xencor, Cullinan Therapeutics, CDR-Life, Ouro Medicines and more. Together, you'll explore how advances in TCE engineering, safety profiling, and translational models are driving a new generation of effective, scalable therapies for autoimmune diseases.
A Snapshot of Your 2025 TCE for Autoimmune Disease Summit Faculty:
What You’ll Gain from the TCE Summit:
Discover how developers are translating lessons from oncology and CAR-T into smarter, more scalable TCE formats tailored for autoimmune indications.
Get frontline insights from rheumatologists to guide trial design, clinical differentiation, and patient selection.
Explore preclinical advances that expand the therapeutic window, minimize CRS, and activate rare immune cell subsets.
Deep-dive into novel biology and targets beyond B cells during our workshop day on precision immunotherapy for autoimmunity.
